- Went public, Oct 2025
- Raised $5.4M funding round, Sep 2025
- Raised $1.8M funding round, Oct 2025
About
TempraMed developed a patent protected technology that can be used in a wide range of Medical/Consumer products, providing temperature control without need for power source or human intervention for years and additionally track medication use. TempraMed already sells products to the first vertical, addressing the need to provide temperature control and management to temperature sensitive injectable medications such as Insulin, EpiPen, Biologics, Hormone, to patients worldwide – a growing market opportunity.
TempraMed’ s product addresses the need of patients, HCP, and payors to make sure medications are tracked and controlled to maintain their potency. While initial target customers for the products are the patients as the products become the standard, they will be adopted by the payors and pharmaceutical companies. The technology used allow the products to be very small and lightweight.
Its smart thermal shield combines a unique ultrahigh vacuum thermal insulation and a small amount of heat absorbing phase change material and uses our unique thermal design. This combination blocks and absorbs heat during the entire day time, and releases the absorbed heat back to the environment overnight, regaining its heat absorbing capacity for the following day, without any intervention.
Funding history · 5 rounds · $10.2M total
Q&A
- What is TempraMed's primary business?
- TempraMed develops patent-protected technology for temperature control and tracking of medication, particularly temperature-sensitive injectable medications like insulin, EpiPen, biologics, and hormones.
- When did TempraMed go public?
- TempraMed went public on the CSE in October 2025.
- What was TempraMed's most recent funding round?
- TempraMed's most recent funding round was in October 2025, raising $1,800,000.
- What is TempraMed's employee count?
- TempraMed has 11-50 employees.
- What is TempraMed's current market capitalization?
- TempraMed's market capitalization is $40,493,359.
- Who are the founders of TempraMed?
- TempraMed was founded by Ron Nagar, who serves as President & CEO, and Elina Nagar, who is the Co-founder & COO.
- What is a recent product launch by TempraMed?
- In January 2026, TempraMed launched a new product called "VIVI Med," aimed at unlocking new growth opportunities in high-value biologics and injectable medications.
- Has TempraMed expanded its manufacturing capacity recently?
- In December 2025, TempraMed expanded its U.S. manufacturing capacity with a new production facility in Florida.
- What is a recent strategic partnership for TempraMed in North America?
- In June 2026, TempraMed expanded its strategic partnership with McKesson Medical-Surgical to accelerate North American growth and launch its full portfolio across B2B channels.
- Has TempraMed secured any recent distribution agreements in the Middle East?
- In June 2026, TempraMed signed a non-binding Letter of Intent with a national distributor in Saudi Arabia.
Team · 2
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
Identifiers & details
| Founded | 2014-10 |
|---|---|
| Employees (exact) | 14 |
| Offices | Sammamish |
| Market cap | $40.5M |
| Status reason | Public on CSE on Oct, 2025; |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| 2025-10 |